Today – February 9, 2019 – the Falsified Medicines Directive 2011/62/EU has come into effect. It requires pharmaceutical manufacturers to provide secondary packaging of prescription medicines with an individual serial number as a 2D code for identification, plus a tamper-evident feature proving that the packaging is intact. This requirement is intended to stop illegal trading of falsified medicines.

Often the less conspicuous a closure seal appears on medicinal packaging the more sophisticated the security technology it contains. Effects that are both conspicuous and unequivocal will only emerge when an informed expert authenticates the seal, like in the case of LumiSecure: Illumination by a special light makes colors on the label visible that can be clearly verified and thus indicate the authenticity of the packaged medicine.

Dumpster diving – this means sifting through containers, typically in search for food. However, medicine counterfeiters have long discovered this “source” as well: They look for empty medicine containers in order to fill them with fake substances. While the mandatory EU Directive makes tampering with secondary packaging more difficult, the risk with primary containers remains – and here first-opening indication would be particularly important: a security gap that Flexi-Cap can effectively close.

Stolen, repackaged, illegally refilled and relabeled: Whether or not a medicine is a copy is often not readily visible. Many counterfeiters have perfected their skills so that even customs and police officers can be deceived. The inconspicuous Covert-Hologram Seal seems to be easy to fake – but when it is opened an effect emerges that no counterfeiter expects.

On 27 June 2018, Uwe Braun (Product Manager Patient Compliance Monitoring Solutions at Schreiner MediPharm) will be speaking about “Smart Packaging as an Enabler for an Outcome Based Healthcare System” at PDA’s 3rd Europe Annual Meeting.

Labels applied to pharmaceutical packaging have evolved into high-tech products featuring a wide variety of functions. The innovative product solutions presented at interpack in Düsseldorf by our Schreiner MediPharm business unit demonstrate these evolutions. Special highlights showcased by Schreiner MediPharm in Hall 7A (Stand B02) include a brand new marking solution for syringes and smart labels with integrated NFC technology

In Europe, our Schreiner MediPharm business unit successfully premiered its new Booklet-Label with integrated closure seal and digital features at Pharmapack in Paris at the beginning of February. Now, the U.S. market launch is coming up at Interphex in New York in mid-March.

There’s a dark side dormant in all of us… Pharmapack visitors will be able to test their criminal skills at Schreiner MediPharm’s booth (M31) in Hall 4 this year. The challenge: Everyone will be invited to try to open Schreiner MediPharm’s closure seals for pharmaceutical packaging without their tampering attempts being detected. This special activity will take place in the light of EU Regulation 2016/161 supplementing the Falsified Medicine Directive, which all pharmaceutical manufacturers of

Our Schreiner MediPharm business unit is also active in the Indian market with its intelligent product solutions for the pharmaceutical industry. This week, our colleagues are presenting their extensive portfolio of specialty labels with additional functions, that enhance and differentiate the final product from the competition due to innovative features, at CPhI India in Mumbai.

The Universe of Pre-filled Syringes & Injection Devices (PDA) conference is focused on pre-filled syringes and injection systems. This year, the annual worldwide industry event was held at Huntington Beach, California, in October, providing a platform for discussion of the latest developments in regulations, technologies and market trends in this field. Our colleagues from Schreiner MediPharm attended the conference, presenting NFC applications and multifunctional solutions for pens and auto